PTS Diagnostics Announces 14 New US and International Patents

Proprietary technologies drive innovation in point-of-care testing

Indianapolis – Feb. 25, 2015 – PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek^® brand and the A1CNow^® family of point-of-care diagnostic products, has been granted 4 new U.S. patents and 10 new patents from Canada, Europe, Germany, India, Korea, and Mexico in just the last 18 months. Since mid-2013, PTS Diagnostics was awarded 5 patents related to its CardioChek test strips, 8 for its A1CNow+ system and one for a new test strip that can test multiple blood chemistries at the same time.

“We continue to develop new and alternative innovations for our CardioChek test strip technology in the US and continue to be granted patents around the globe as we expand distribution of our A1CNow+ system to additional countries,” said Robert Huffstodt, President and CEO of PTS Diagnostics. “This technology ensures we deliver accurate and precise lipid, glucose and A1C testing and monitoring.”

In approximately the last 18 months, PTS Diagnostics was granted these new patents:

United States: #8,460,539; #8,465,696; #8,642,320; #8,865,089

Canada: #2,654,292

Europe: #1 474 692; #1 725 650; #2 221 621

Germany: #112,012,000,32

Korea: #10-1,324,375, #10-1,347,472

India: #258,142; #257,235

Mexico: #315,864

PTS Diagnostics currently holds 91 U.S. and international patents and has 86 pending patent applications.

“As we look to the future, we are anticipating the needs of our customers and are working diligently to create next-generation technology to expand the testing and services we provide,” said Huffstodt. “These new patents, combined with our pending applications, will fuel PTS Diagnostics’ growth in the future. We continue to have a robust pipeline of new innovation and look forward to the next year and beyond.”

PTS Diagnostics’ products are sold in more than 120 countries and its CardioChek analyzers have screened more than 120 million people worldwide. In addition, sales of its A1CNow System surpassed 1 million tests in just 8 months after the company began manufacturing the A1C monitoring device.

PTS Diagnostics’ handheld, highly-accurate, fast, and economical diagnostic devices empower the medical community to quickly measure HbA1c and glucose, and generate a lipid (cholesterol) profile, all at the point of care.

PTS Diagnostics’ portfolio includes the following systems:

 CardioChek professional analyzers address the connection between heart attack, stroke, and diabetes by providing on-site lipid panel (total cholesterol, HDL cholesterol, and triglycerides) screening results in as little as 90 seconds and can also measure glucose. CardioChek professional analyzers calculate LDL cholesterol, the TC/HDL ratio, the LDL/HDL ratio, and non-HDL cholesterol.

 The A1CNow+ system provides healthcare professionals with a fast, easy, and accurate method of obtaining HbA1c results while the patient is in the exam room. In just five minutes, clinicians have information to provide an immediate consultation with a patient. The A1CNow+ system is critical to diabetes management and is fully reimbursable.

About PTS Diagnostics – PTS Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, PTS Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. PTS Diagnostics’ products include both the CardioChek systems and A1CNow systems.

All trademarks used or mentioned in this release are protected by law.

For more information, visit www.ptsdiagnostics.com or contact Tom Wiser at +1-317-870-5610.

MKG001306 Rev. 0 2/15